<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7460442\results\search\disease\results.xml">
  <result pre="of public health concerns is going on with the Coronavirus" exact="Disease" post="2019 (COVID-19), which is caused by severe acute respiratory"/>
  <result pre="the Coronavirus Disease 2019 (COVID-19), which is caused by severe" exact="acute" post="respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of COVID-19"/>
  <result pre="Coronavirus Disease 2019 (COVID-19), which is caused by severe acute" exact="respiratory" post="syndrome coronavirus-2 (SARS-CoV-2). The first case of COVID-19 was"/>
  <result pre="Disease 2019 (COVID-19), which is caused by severe acute respiratory" exact="syndrome" post="coronavirus-2 (SARS-CoV-2). The first case of COVID-19 was reported"/>
  <result pre="virus. Thanks to its high pathogenicity, it can cause severe" exact="respiratory" post="infections. Fever, dry cough, sore throat, pneumonia, septic shock,"/>
  <result pre="cause severe respiratory infections. Fever, dry cough, sore throat, pneumonia," exact="septic shock," post="and ground-glass opacities are the foremost clinical manifestations of"/>
  <result pre="of COVID-19. Immunocompromised patients are at high risk for COVID-19" exact="infection" post="and may lead to death. Scientist and government agencies"/>
  <result pre="drugs are available for the treatment of human coronaviruses (HCoV)" exact="infections" post="such as SARS (severe acute respiratory syndrome), MERS (Middle"/>
  <result pre="treatment of human coronaviruses (HCoV) infections such as SARS (severe" exact="acute" post="respiratory syndrome), MERS (Middle Eastern respiratory syndrome), and COVID-19."/>
  <result pre="of human coronaviruses (HCoV) infections such as SARS (severe acute" exact="respiratory" post="syndrome), MERS (Middle Eastern respiratory syndrome), and COVID-19. Since"/>
  <result pre="such as SARS (severe acute respiratory syndrome), MERS (Middle Eastern" exact="respiratory" post="syndrome), and COVID-19. Since the outbreak, a plethora of"/>
  <result pre="changed to â€œSARS-CoV-2â€� owing to its high similarity to severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) [2]. Finally, it became popular"/>
  <result pre="to â€œSARS-CoV-2â€� owing to its high similarity to severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) [2]. Finally, it became popular as"/>
  <result pre="â€œSARS-CoV-2â€� owing to its high similarity to severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) [2]. Finally, it became popular as Coronavirus"/>
  <result pre="syndrome coronavirus (SARS-CoV) [2]. Finally, it became popular as Coronavirus" exact="Disease" post="2019 (COVID-19) [3]. Scientists and governments around the globe"/>
  <result pre="nor antiviral drugs are approved for the treatment of HCoV" exact="infections" post="such as SARS, MERS (Middle Eastern respiratory syndrome), and"/>
  <result pre="treatment of HCoV infections such as SARS, MERS (Middle Eastern" exact="respiratory" post="syndrome), and the COVID-19 [4,5,6,7]. The word â€œcoronaâ€� is"/>
  <result pre="These coronaviruses are highly contagious [15] and can cause severe" exact="respiratory" post="infection [16] and acute respiratory distress syndrome (ARDS), followed"/>
  <result pre="coronaviruses are highly contagious [15] and can cause severe respiratory" exact="infection" post="[16] and acute respiratory distress syndrome (ARDS), followed by"/>
  <result pre="contagious [15] and can cause severe respiratory infection [16] and" exact="acute" post="respiratory distress syndrome (ARDS), followed by acute lung injury"/>
  <result pre="[15] and can cause severe respiratory infection [16] and acute" exact="respiratory" post="distress syndrome (ARDS), followed by acute lung injury (ALI),"/>
  <result pre="can cause severe respiratory infection [16] and acute respiratory distress" exact="syndrome" post="(ARDS), followed by acute lung injury (ALI), leading to"/>
  <result pre="infection [16] and acute respiratory distress syndrome (ARDS), followed by" exact="acute" post="lung injury (ALI), leading to pulmonary failure and, ultimately,"/>
  <result pre="syndrome (ARDS), followed by acute lung injury (ALI), leading to" exact="pulmonary" post="failure and, ultimately, death [17]. The current strain of"/>
  <result pre="been shown that bat CoVs can infect humans without an" exact="intermediate" post="carrier [23,24]. It is suggested that SARS-CoV-2 originated from"/>
  <result pre="very much similar to SARS-CoV-2. Furthermore, there may be an" exact="intermediate" post="host between humans and bats. The pangolin, an animal"/>
  <result pre="and prevention and control pathways. 2. Structure of SARS-CoV-2 The" exact="viral" post="genome of SARS-CoV-2 is composed of 29,903 nucleotides and"/>
  <result pre="(M), envelope (E), and nucleocapsid (N) proteins. In addition, two" exact="viral" post="replicase polyproteins termed PP1a and PP1ab are produced by"/>
  <result pre="virus to attach to the ACE2 receptor, which spans the" exact="respiratory" post="tract lining. The second critical mutation permitted the virus"/>
  <result pre="on 7 January 2020. In response, the sequence of the" exact="viral" post="genome was published by Chinese scientists on 10 January"/>
  <result pre="22 January 2020. On 25 January 2020, there were a" exact="total" post="of 1975 infected patients in China, out of which"/>
  <result pre="[40]. According to another report from 30 January 2020, a" exact="total" post="of 7734 cases were reported in China, and 90"/>
  <result pre="Singapore, France, Germany, and Taiwan [41]. The Chinese Center for" exact="Disease" post="Control and Prevention reported 44,672 confirmed cases by 11"/>
  <result pre="Previously, it was thought that children were less susceptible to" exact="infection" post="owing to a lack of evidence, but on 5"/>
  <result pre="States on 13 March 2020. By 27 March 2020, the" exact="total" post="number of infected patients reached half a million, and"/>
  <result pre="by the CDC and the WHO to manage the escalating" exact="disease" post="[46]. Another parameter for understanding the severity and prognosis"/>
  <result pre="[46]. Another parameter for understanding the severity and prognosis of" exact="infection" post="is the case fatality ratio (CFR), which is calculated"/>
  <result pre="calculated by dividing the number of expired patients by the" exact="total" post="number of diagnosed patients, multiplied by 100. According to"/>
  <result pre="geriatrics, especially over 80 [48]. 5. Pathogenesis SARS-CoV-2 targets the" exact="lower" post="respiratory tract and causes mild to severe symptoms. COVID-19"/>
  <result pre="especially over 80 [48]. 5. Pathogenesis SARS-CoV-2 targets the lower" exact="respiratory" post="tract and causes mild to severe symptoms. COVID-19 patients"/>
  <result pre="SARS-CoV and MERS-CoV [49]. Although the pathogenesis of novel coronavirus" exact="disease" post="is not fully understood, the similarity of novel coronavirus"/>
  <result pre="of COVID-19 infection. The body shows aggressive inflammatory responses after" exact="viral" post="entry, and it may cause severe damage to airways."/>
  <result pre="airways. The pathogenicity is increased by a large number of" exact="viral" post="copies replicated in the cell. The life cycle of"/>
  <result pre="cell [50]. Coronavirus enters the cell by its sole determinant" exact="viral" post="S-protein and undergoes several steps to accomplish the replication."/>
  <result pre="and the S2 domain accounts for the fusion of the" exact="viral" post="membrane with the cell membrane [51]. The viral spike"/>
  <result pre="of the viral membrane with the cell membrane [51]. The" exact="viral" post="spike glycoproteins attach themselves to the ACE2 receptor of"/>
  <result pre="S2 domain, which accounts for fusion and infection. After the" exact="viral" post="entry, the RNA genome of the virus is released"/>
  <result pre="the virus continues to replicate [56]. After the formation of" exact="viral" post="proteins by translation, these new proteins are inserted into"/>
  <result pre="are inserted into the endoplasmic reticulum or Golgi apparatus. When" exact="viral" post="RNA is combined with the proteins, the nucleocapsid is"/>
  <result pre="enclosed in the vesicles are released by exocytosis [56]. The" exact="viral" post="release marks the time when infected patients start displaying"/>
  <result pre="start displaying significant symptoms and laboratory values. Higher leukocyte count," exact="respiratory" post="problems, and exaggerated pro-inflammatory cytokines are exhibited by COVID-19"/>
  <result pre="culture showed a positive result for COVID-19 and confirmed the" exact="disease" post="[57]. The laboratory analysis showed a leukocyte count of"/>
  <result pre="erythrocyte sedimentation rate (ESR) was also high with D-dimer. The" exact="primary" post="pathogenesis of the nCoV is associated with respiratory infections,"/>
  <result pre="D-dimer. The primary pathogenesis of the nCoV is associated with" exact="respiratory" post="infections, pneumonia, ground-glass opacities (GGOs), acute cardiac injury, ARDS,"/>
  <result pre="nCoV is associated with respiratory infections, pneumonia, ground-glass opacities (GGOs)," exact="acute" post="cardiac injury, ARDS, and RNAaemia [38]. Additionally, high blood"/>
  <result pre="MIP1Î±, GCSF, and TNFÎ±, which exaggerated the severity of the" exact="infection" post="[58]. This exaggerated immune response destroys the lungâ€™s infrastructure"/>
  <result pre="attaches to the ACE2 receptor. TMPRSS2 is responsible for the" exact="viral" post="protein cleavage. Protease inhibitors can be designed and developed"/>
  <result pre="designed and developed to prevent spike protein cleavage. Blocking the" exact="viral" post="fusion through either TMPRSS2 or receptor ACE2 can prevent"/>
  <result pre="[60]. ARDS seen in several COVID-19 patients may lead to" exact="secondary" post="infections, and respiratory failure leads to death in 79%"/>
  <result pre="in several COVID-19 patients may lead to secondary infections, and" exact="respiratory" post="failure leads to death in 79% of critical cases."/>
  <result pre="exaggerated immune response responsible for the enhanced severity of the" exact="infection" post="[60,62]. As discussed earlier, ACE2 is the receptor for"/>
  <result pre="get insight into the relationship between the prevalence of COVID-19" exact="disease" post="and the genetic differences in the genes involved in"/>
  <result pre="between 2.1 and 11.1 days with possible asymptomatic transmission [64]." exact="Infection" post="is manifested after the incubation period. The period from"/>
  <result pre="after the incubation period. The period from the commencement of" exact="disease" post="leading to death fluctuates between 6 and 41 days"/>
  <result pre="50% of the patients [8]. Fewer patients may also develop" exact="kidney damage," post="ARDS, septic shock, and acute cardiac injury requiring hospitalization"/>
  <result pre="patients [8]. Fewer patients may also develop kidney damage, ARDS," exact="septic shock," post="and acute cardiac injury requiring hospitalization [67]. The clinical"/>
  <result pre="patients may also develop kidney damage, ARDS, septic shock, and" exact="acute" post="cardiac injury requiring hospitalization [67]. The clinical symptoms are"/>
  <result pre="symptoms are presented in Table 2. Mutual laboratory findings include" exact="lymphopenia" post="and leucopenia. These findings were common and observed in"/>
  <result pre="[68]. Chest computed tomography (CT) scan showed clinical features including" exact="pneumonia" post="and other abnormal features, for instance, RNAaemia, acute cardiac"/>
  <result pre="features including pneumonia and other abnormal features, for instance, RNAaemia," exact="acute" post="cardiac injury, and occurrence of GGO, that set the"/>
  <result pre="GGOs were observed in both lungs, which expectedly triggers the" exact="systemic" post="and localized immune reaction, causing severe inflammation [65]. Atypical"/>
  <result pre="observed in both lungs, which expectedly triggers the systemic and" exact="localized" post="immune reaction, causing severe inflammation [65]. Atypical CT scan"/>
  <result pre="the systemic and localized immune reaction, causing severe inflammation [65]." exact="Atypical" post="CT scan showed single, multiple solid, and consolidated nodules"/>
  <result pre="of COVID-19 are fever, fatigue, and dry cough. In contrast," exact="upper" post="respiratory tract symptoms like rhinorrhea, sore throat, and sneezing"/>
  <result pre="COVID-19 are fever, fatigue, and dry cough. In contrast, upper" exact="respiratory" post="tract symptoms like rhinorrhea, sore throat, and sneezing are"/>
  <result pre="like diarrhea, which were less prevalent in MERS-CoV and SARS-CoV" exact="infections" post="[70]. In addition, patients may also report anosmia and"/>
  <result pre="sense of taste) are also associated with COVID-19 patients. The" exact="American" post="Academy of Otolaryngology-Head and Neck Surgery developed the COVID-19"/>
  <result pre="[80]. This approach allowed to test a huge number of" exact="symptomatic" post="individuals rapidly in the community, minimizing the waiting time"/>
  <result pre="a confirmed case [76]. Meanwhile, a CT scan of the" exact="chest" post="provides confirmed diagnostic evidence of COVID-19 disease as it"/>
  <result pre="scan of the chest provides confirmed diagnostic evidence of COVID-19" exact="disease" post="as it has greater sensitivity and high specificity. Thus,"/>
  <result pre="as it has greater sensitivity and high specificity. Thus, the" exact="chest" post="CT has been recognized as a significant indicator for"/>
  <result pre="different epidemic areas [15,31,81]. It can be said that the" exact="chest" post="CT is an essential procedure for the timely detection"/>
  <result pre="that a patient with an RT-PCR may have a negative" exact="chest" post="CT at the time of admission [82]. In this"/>
  <result pre="COVID-19 does not cross-react with other types of coronaviruses and" exact="respiratory" post="microorganisms in the cellular medium. In contrast, the RdRp-P2"/>
  <result pre="reported for previous coronaviruses, reacts with the pathogens of the" exact="respiratory" post="tract in the cell culture. Thus, the COVID-19-RdRp/Hel can"/>
  <result pre="cases for COVID-19 patients [85]. Another cohort study suggested that" exact="lymphopenia" post="(low levels of lymphocytes) occurred in 80% of COVID-19"/>
  <result pre="regimen is available for the treatment of COVID-19. However, the" exact="primary" post="step is isolation to prevent any type of contact"/>
  <result pre="counseling to patients about the critical signs and symptoms. The" exact="primary" post="management protocols include the management of cough and fever"/>
  <result pre="are used for non-productive cough [90]. Patients with SARS, hypoxemia," exact="respiratory" post="distress or shock should be treated by the administration"/>
  <result pre="[91]. Antiviral therapy is also being tried to manage the" exact="infection" post="[92]. Critical patients show an unhealthy immune response that"/>
  <result pre="discussed earlier, inflammatory cytokines are released at the site of" exact="infection" post="and cause infiltration of lungs. Clinical trials are underway"/>
  <result pre="in the cell to adenosine triphosphate analog, which inhibits the" exact="viral" post="RNA polymerases. Remdesivir is the drug of choice against"/>
  <result pre="RNA polymerases. Remdesivir is the drug of choice against several" exact="viral" post="families, including Ebola, SARS-CoV, and MERS-CoV. Remdesivir is being"/>
  <result pre="lopinavir. These medications are prescribed to be taken for a" exact="short" post="period of time (&amp;lt;2 weeks), suggesting their acute response."/>
  <result pre="for a short period of time (&amp;lt;2 weeks), suggesting their" exact="acute" post="response. Hydroxychloroquine, lopinavir/ritonavir, chloroquine, and darunavir/cobicistat are being used"/>
  <result pre="on the specific activity of oseltamivir against COVID-19. A 54-year-old" exact="female" post="patient from Wuhan city presented with fever for the"/>
  <result pre="woman was treated with oseltamivir for three days, and her" exact="chest" post="CT indicated reminiscent improvement in the density of GGO"/>
  <result pre="adults. It is believed to reduce the prognosis of the" exact="disease" post="in patients with impaired oxygen index, that is, less"/>
  <result pre="impaired oxygen index, that is, less than 300 mm Hg," exact="limited" post="to 5 days [69]. For patients with premature disease"/>
  <result pre="Hg, limited to 5 days [69]. For patients with premature" exact="disease" post="stage, without hypoxia, use of corticosteroids should be avoided."/>
  <result pre="the aid of mechanical ventilation or oxygen alone resulted in" exact="lower" post="mortality at the dose of 6 mg once daily"/>
  <result pre="was not effective in those patients who were not receiving" exact="respiratory" post="support [113]. Dexamethasone is on an essential medicines list"/>
  <result pre="penciclovir, ribavirin, and favipiravir require high doses to decrease the" exact="infection" post="and are supposed to be less effective [90]. Chloroquine"/>
  <result pre="COVID-19 and are currently used in Chinese patients to reduce" exact="viral infection." post="Potential drug therapy for COVID-19 is listed in Table"/>
  <result pre="mg/day) treatment is magnificently related to a decreased rate of" exact="viral" post="replication in patients, and its effectiveness is reinforced by"/>
  <result pre="many reports, the COVID-19 patients are at high risk for" exact="venous thromboembolism," post="a term that associates deep vein thrombosis (DVT) [119]."/>
  <result pre="at high risk for venous thromboembolism, a term that associates" exact="deep vein thrombosis" post="(DVT) [119]. In this context, patients are treated prophylactically"/>
  <result pre="risk for venous thromboembolism, a term that associates deep vein" exact="thrombosis" post="(DVT) [119]. In this context, patients are treated prophylactically"/>
  <result pre="the drugs, including chloroquine, promazine, and emodine, to prevent the" exact="viral" post="attachment with the surface of the host cell [122]."/>
  <result pre="[122]. S protein priming is the next precarious phase of" exact="viral" post="entry into the host cell, where it is required"/>
  <result pre="proteases including TMPRSS2, cathepsins, and furin for the fusion of" exact="viral" post="membrane with the cell membrane of the host. S-protein"/>
  <result pre="TMPRSS2 is the most crucial phase for the prognosis of" exact="infection" post="into the host, so the viral infection can be"/>
  <result pre="for the prognosis of infection into the host, so the" exact="viral infection" post="can be controlled with the use of protease inhibitors,"/>
  <result pre="the prognosis of infection into the host, so the viral" exact="infection" post="can be controlled with the use of protease inhibitors,"/>
  <result pre="camostat and nafamostat, which target TMPRSS2, and thereby inhibit the" exact="viral" post="fusion [123]. The immune system represents the defensive mechanism"/>
  <result pre="therapy of azithromycin with hydroxychloroquine showed significant activity against COVID-19" exact="infection" post="[124]. Table 5 delineates the potential therapeutics against COVID-19."/>
  <result pre="the use of vitamin D in decreasing the probability of" exact="respiratory" post="infections caused by COVID-19. As vitamin D induces the"/>
  <result pre="use of vitamin D in decreasing the probability of respiratory" exact="infections" post="caused by COVID-19. As vitamin D induces the antimicrobial"/>
  <result pre="such as defensins and cathelicidins that eventually interfere with the" exact="viral" post="growth and pro-inflammatory cytokines, more evaluation is needed by"/>
  <result pre="is being developed by the National Institute of Allergy and" exact="Infectious" post="Disease researchers combined with biotechnology institution Moderna. In this"/>
  <result pre="being developed by the National Institute of Allergy and Infectious" exact="Disease" post="researchers combined with biotechnology institution Moderna. In this case,"/>
  <result pre="to evaluate the pathogenesis and clinical features for combating the" exact="disease" post="by approaching a series of therapeutic options and development"/>
  <result pre="of reinfection. To address this concern, Bao et al. investigated" exact="acquired" post="immunity to SARS-CoV-2 in rhesus macaques. This study published"/>
  <result pre="in rhesus macaques. This study published recently suggests that immunity" exact="acquired" post="following primary infection with SARS-CoV-2 may protect upon subsequent"/>
  <result pre="macaques. This study published recently suggests that immunity acquired following" exact="primary" post="infection with SARS-CoV-2 may protect upon subsequent exposure to"/>
  <result pre="This study published recently suggests that immunity acquired following primary" exact="infection" post="with SARS-CoV-2 may protect upon subsequent exposure to the"/>
  <result pre="and Control Several methods have been implemented based on actual" exact="infection" post="control and segregation to control the transmission of COVID-19."/>
  <result pre="are sneezing and coughing should be maintained. People should uphold" exact="respiratory" post="hygiene, such as covering nose and mouth during coughing."/>
  <result pre="is to minimize the exposure to the virus. Center for" exact="Disease" post="Control, USA, WHO, and the Chinese CDC have provided"/>
  <result pre="This review provides insight into various aspects of COVID-19, including" exact="disease" post="pathophysiology, its clinical representation, mechanism of drugs actions, and"/>
  <result pre="to their unfavorable side effect profile, their use should be" exact="limited" post="to a short period of time in critical patients."/>
  <result pre="side effect profile, their use should be limited to a" exact="short" post="period of time in critical patients. It needs to"/>
  <result pre="compounds such as remdesivir inhibit RNA transcription, leading to reduced" exact="viral" post="load. This class of drugs is potentially the most"/>
  <result pre="their long-term clinical outcomes as of this day, drugs targeting" exact="viral" post="RNA are the most promising tools in this battle."/>
  <result pre="Marshall B. Ketchum University, Fullerton, CA, USA and University of" exact="Central" post="Punjab, Lahore, Pakistan. Author Contributions The manuscript was written"/>
  <result pre="published version of the manuscript. Funding This research received no" exact="external" post="funding and the APC was funded by College of"/>
  <result pre="The authors declare no conflict of interest. Abbreviations SARS severe" exact="acute" post="respiratory syndrome MERS Middle Eastern respiratory syndrome PHEIC public"/>
  <result pre="authors declare no conflict of interest. Abbreviations SARS severe acute" exact="respiratory" post="syndrome MERS Middle Eastern respiratory syndrome PHEIC public health"/>
  <result pre="declare no conflict of interest. Abbreviations SARS severe acute respiratory" exact="syndrome" post="MERS Middle Eastern respiratory syndrome PHEIC public health emergency"/>
  <result pre="interest. Abbreviations SARS severe acute respiratory syndrome MERS Middle Eastern" exact="respiratory" post="syndrome PHEIC public health emergency of international concern NHC"/>
  <result pre="Abbreviations SARS severe acute respiratory syndrome MERS Middle Eastern respiratory" exact="syndrome" post="PHEIC public health emergency of international concern NHC National"/>
  <result pre="of international concern NHC National Health Commission CoV coronavirus ARDS" exact="acute" post="respiratory distress syndrome ALI acute lung injury GISAID global"/>
  <result pre="international concern NHC National Health Commission CoV coronavirus ARDS acute" exact="respiratory" post="distress syndrome ALI acute lung injury GISAID global initiative"/>
  <result pre="NHC National Health Commission CoV coronavirus ARDS acute respiratory distress" exact="syndrome" post="ALI acute lung injury GISAID global initiative on sharing"/>
  <result pre="Health Commission CoV coronavirus ARDS acute respiratory distress syndrome ALI" exact="acute" post="lung injury GISAID global initiative on sharing all influenza"/>
  <result pre="receptor BCG Bacillus Calmetteâ€&quot;GuÃ©rin References References 1.collab: World Health OrganizationCoronavirus" exact="Disease" post="(COVID-19) Situation Report 121, Data as Received by WHO"/>
  <result pre="COVID-19 is higher compared to SARS coronavirusJ. Travel Med.20202710.1093/jtm/taaa021 3.GorbalenyaA.E.Severe" exact="acute" post="respiratory syndrome-related coronavirusâ€&quot;The species and its viruses, a statement"/>
  <result pre="is higher compared to SARS coronavirusJ. Travel Med.20202710.1093/jtm/taaa021 3.GorbalenyaA.E.Severe acute" exact="respiratory" post="syndrome-related coronavirusâ€&quot;The species and its viruses, a statement of"/>
  <result pre="Res. Public Health202017269010.3390/ijerph1708269032295188 8.RenL.-L.WangY.-M.WuZ.-Q.XiangZ.-C.GuoL.XuT.JiangY.-Z.XiongY.LiY.-J.LiH.Identification of a novel coronavirus causing severe" exact="pneumonia" post="in human: A descriptive studyChin. Med. J.20201331015102410.1097/CM9.000000000000072232004165 9.collab: World"/>
  <result pre="studyChin. Med. J.20201331015102410.1097/CM9.000000000000072232004165 9.collab: World Health OrganizationLaboratory Testing for Coronavirus" exact="Disease" post="2019 (COVID-19) in Suspected Human Cases: Interim Guidance, 2"/>
  <result pre="review of the 2019 novel coronavirus (COVID-19)Int. J. Surg.202076717610.1016/j.ijsu.2020.02.03432112977 11.ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="coronavirus of probable bat originNature202057927027310.1038/s41586-020-2012-732015507 12.LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.ToK.A major outbreak of severe" exact="acute" post="respiratory syndrome in Hong KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 13.ZakiA.M.Van"/>
  <result pre="of probable bat originNature202057927027310.1038/s41586-020-2012-732015507 12.LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.ToK.A major outbreak of severe acute" exact="respiratory" post="syndrome in Hong KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 13.ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation"/>
  <result pre="probable bat originNature202057927027310.1038/s41586-020-2012-732015507 12.LeeN.HuiD.WuA.ChanP.CameronP.JoyntG.M.AhujaA.YungM.Y.LeungC.ToK.A major outbreak of severe acute respiratory" exact="syndrome" post="in Hong KongN. Engl. J. Med.20033481986199410.1056/NEJMoa03068512682352 13.ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of"/>
  <result pre="13.ZakiA.M.Van BoheemenS.BestebroerT.M.OsterhausA.D.FouchierR.A.Isolation of a novel coronavirus from a man with" exact="pneumonia" post="in Saudi ArabiaN. Engl. J. Med.20123671814182010.1056/NEJMoa121172123075143 14.WangL.-F.ShiZ.ZhangS.FieldH.DaszakP.EatonB.T.Review of bats"/>
  <result pre="with human receptor DPP4Cell Res.20132398610.1038/cr.2013.9223835475 17.ZhongN.ZhengB.LiY.PoonL.XieZ.ChanK.LiP.TanS.ChangQ.XieJ.Epidemiology and cause of severe" exact="acute" post="respiratory syndrome (SARS) in Guangdong, Peopleâ€™s Republic of China,"/>
  <result pre="human receptor DPP4Cell Res.20132398610.1038/cr.2013.9223835475 17.ZhongN.ZhengB.LiY.PoonL.XieZ.ChanK.LiP.TanS.ChangQ.XieJ.Epidemiology and cause of severe acute" exact="respiratory" post="syndrome (SARS) in Guangdong, Peopleâ€™s Republic of China, in"/>
  <result pre="receptor DPP4Cell Res.20132398610.1038/cr.2013.9223835475 17.ZhongN.ZhengB.LiY.PoonL.XieZ.ChanK.LiP.TanS.ChangQ.XieJ.Epidemiology and cause of severe acute respiratory" exact="syndrome" post="(SARS) in Guangdong, Peopleâ€™s Republic of China, in February,"/>
  <result pre="health concernLancet202039547047310.1016/S0140-6736(20)30185-931986257 22.GuoY.-R.CaoQ.-D.HongZ.-S.TanY.-Y.ChenS.-D.JinH.-J.TanK.-S.WangD.-Y.YanY.The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;An update on the statusMil. Med. Res.2020711010.1186/s40779-020-00240-031928528"/>
  <result pre="update on the statusMil. Med. Res.2020711010.1186/s40779-020-00240-031928528 23.ChakrabortyC.SharmaA.R.BhattacharyaM.SharmaG.LeeS.-S.The 2019 novel coronavirus" exact="disease" post="(COVID-19) pandemic: A zoonotic prospectiveAsian Pac. J. Trop. Med.202013242246"/>
  <result pre="cleavage site predicted in the spike protein of the novel" exact="pneumonia" post="coronavirus (2019-nCoV) potentially related to viral transmissibilityVirol. Sin.20201310.1007/s12250-020-00212-731916022 35.MatyÃ¡Å¡ekR.KovaÅ™Ã­kA.Mutation"/>
  <result pre="protein of the novel pneumonia coronavirus (2019-nCoV) potentially related to" exact="viral" post="transmissibilityVirol. Sin.20201310.1007/s12250-020-00212-731916022 35.MatyÃ¡Å¡ekR.KovaÅ™Ã­kA.Mutation Patterns of Human SARS-CoV-2 and Bat"/>
  <result pre="epidemiology of Covid-19â€&quot;Studies neededN. Engl. J. Med.20203821194119610.1056/NEJMp200212532074416 37.YuanH.CaoX.JiX.DuF.ZhouX.HeJ.XieY.ZhuY.A Current Emerging" exact="Respiratory" post="Infection: Epidemiological and Clinical Characteristics, Diagnosis and Treatments of"/>
  <result pre="China, 2020J. Clin. Med.2020933010.3390/jcm9020330 41.RothanH.A.ByrareddyS.N.The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreakJ. Autoimmun.202010910243310.1016/j.jaut.2020.10243332113704 42.collab: Epidemiology Working Group for NCIP"/>
  <result pre="disease (COVID-19) outbreakJ. Autoimmun.202010910243310.1016/j.jaut.2020.10243332113704 42.collab: Epidemiology Working Group for NCIP" exact="Epidemic" post="Responsecollab: Chinese Center for Disease Control and PreventionThe epidemiological"/>
  <result pre="Epidemiology Working Group for NCIP Epidemic Responsecollab: Chinese Center for" exact="Disease" post="Control and PreventionThe epidemiological characteristics of an outbreak of"/>
  <result pre="22 April 2020) 45.ReadM.C.EID: High Contagiousness and Rapid Spread of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 46.YangY.PengF.WangR.GuanK.JiangT.XuG.SunJ.ChangC.The deadly"/>
  <result pre="April 2020) 45.ReadM.C.EID: High Contagiousness and Rapid Spread of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 46.YangY.PengF.WangR.GuanK.JiangT.XuG.SunJ.ChangC.The deadly coronaviruses:"/>
  <result pre="2020) 45.ReadM.C.EID: High Contagiousness and Rapid Spread of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 46.YangY.PengF.WangR.GuanK.JiangT.XuG.SunJ.ChangC.The deadly coronaviruses: The"/>
  <result pre="45.ReadM.C.EID: High Contagiousness and Rapid Spread of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2Emerg. Infect. Dis.20202610.3201/eid2607.200282 46.YangY.PengF.WangR.GuanK.JiangT.XuG.SunJ.ChangC.The deadly coronaviruses: The 2003"/>
  <result pre="Sci. USA20201179696969810.1073/pnas.200491111732300018 48.WuZ.McGooganJ.M.Characteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: Summary of a report"/>
  <result pre="report of 72 314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA20203231239124210.1001/jama.2020.264832091533 49.PeirisJ.GuanY.YuenK.Severe acute respiratory syndromeNat. Med.200410S88S9710.1038/nm114315577937 50.JahangirM.A.Coronavirus"/>
  <result pre="from the Chinese Center for Disease Control and PreventionJAMA20203231239124210.1001/jama.2020.264832091533 49.PeirisJ.GuanY.YuenK.Severe" exact="acute" post="respiratory syndromeNat. Med.200410S88S9710.1038/nm114315577937 50.JahangirM.A.Coronavirus (COVID-19): History, Current Knowledge and"/>
  <result pre="the Chinese Center for Disease Control and PreventionJAMA20203231239124210.1001/jama.2020.264832091533 49.PeirisJ.GuanY.YuenK.Severe acute" exact="respiratory" post="syndromeNat. Med.200410S88S9710.1038/nm114315577937 50.JahangirM.A.Coronavirus (COVID-19): History, Current Knowledge and Pipeline"/>
  <result pre="coronavirusCell. Mol. Life Sci.2004612738274310.1007/s00018-004-4242-515549175 53.WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526910.1038/s41586-020-2008-332015508 54.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe acute respiratory syndrome-associated"/>
  <result pre="Mol. Life Sci.2004612738274310.1007/s00018-004-4242-515549175 53.WuF.ZhaoS.YuB.ChenY.-M.WangW.SongZ.-G.HuY.TaoZ.-W.TianJ.-H.PeiY.-Y.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526910.1038/s41586-020-2008-332015508 54.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe acute respiratory syndrome-associated coronavirus"/>
  <result pre="associated with human respiratory disease in ChinaNature202057926526910.1038/s41586-020-2008-332015508 54.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entryProc. Natl."/>
  <result pre="with human respiratory disease in ChinaNature202057926526910.1038/s41586-020-2008-332015508 54.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entryProc. Natl. Acad."/>
  <result pre="54.SimmonsG.ReevesJ.D.RennekampA.J.AmbergS.M.PieferA.J.BatesP.Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated" exact="viral" post="entryProc. Natl. Acad. Sci. USA20041014240424510.1073/pnas.030644610115010527 55.BelouzardS.ChuV.C.WhittakerG.R.Activation of the SARS"/>
  <result pre="on replication and pathogenesisNat. Rev. Genet.2009743945010.1038/nrmicro214719430490 57.GuanW.-J.NiZ.-Y.HuY.LiangW.-H.OuC.-Q.HeJ.-X.LiuL.ShanH.LeiC.-L.HuiD.S.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN. Engl. J. Med.20203821708172010.1056/NEJMoa200203232109013 58.MehtaP.McAuleyD.F.BrownM.SanchezE.TattersallR.S.MansonJ.J.COVID-19: Consider cytokine"/>
  <result pre="Ecological Meta-RegressionSpringerBerlin/Heidelberg, Germany2020 64.BackerJ.A.KlinkenbergD.WallingaJ.Incubation period of 2019 novel coronavirus (2019-nCoV)" exact="infections" post="among travellers from Wuhan, China, 20â€&quot;28 January 2020Eurosurveillance20202510.2807/1560-7917.ES.2020.25.5.2000062 65.NgM.-Y.LeeE.Y.YangJ.YangF.LiX.WangH.LuiM.M.-S.LoC.S.-Y.LeungB.KhongP.-L.Imaging"/>
  <result pre="epidemiological and clinical features of the emerging 2019 novel coronavirus" exact="pneumonia" post="(COVID-19) implicate special control measuresJ. Med. Virol.20209256857610.1002/jmv.2574832134116 67.PanX.-W.XuH.Z.D.ZhouW.WangL.-H.CuiX.-G.Identification of"/>
  <result pre="control measuresJ. Med. Virol.20209256857610.1002/jmv.2574832134116 67.PanX.-W.XuH.Z.D.ZhouW.WangL.-H.CuiX.-G.Identification of a potential mechanism of" exact="acute" post="kidney injury during the COVID-19 outbreak: A study based"/>
  <result pre="measuresJ. Med. Virol.20209256857610.1002/jmv.2574832134116 67.PanX.-W.XuH.Z.D.ZhouW.WangL.-H.CuiX.-G.Identification of a potential mechanism of acute" exact="kidney injury" post="during the COVID-19 outbreak: A study based on single-cell"/>
  <result pre="anti-inflammatory drugs in the treatment of people with severe coronavirus" exact="disease" post="2019 (COVID-19): The experience of clinical immunologists from ChinaClin."/>
  <result pre="75.collab: World Health OrganizationWHO Guidelines for the Global Surveillance of" exact="Severe" post="Acute Respiratory Syndrome (SARS): Updated Recommendations, October 2004WHO PressGeneva,"/>
  <result pre="World Health OrganizationWHO Guidelines for the Global Surveillance of Severe" exact="Acute" post="Respiratory Syndrome (SARS): Updated Recommendations, October 2004WHO PressGeneva, Switzerland2004"/>
  <result pre="Health OrganizationWHO Guidelines for the Global Surveillance of Severe Acute" exact="Respiratory" post="Syndrome (SARS): Updated Recommendations, October 2004WHO PressGeneva, Switzerland2004 76.ZuZ.Y.JiangM.D.XuP.P.ChenW.NiQ.Q.LuG.M.ZhangL.J.Coronavirus"/>
  <result pre="OrganizationWHO Guidelines for the Global Surveillance of Severe Acute Respiratory" exact="Syndrome" post="(SARS): Updated Recommendations, October 2004WHO PressGeneva, Switzerland2004 76.ZuZ.Y.JiangM.D.XuP.P.ChenW.NiQ.Q.LuG.M.ZhangL.J.Coronavirus disease"/>
  <result pre="Respiratory Syndrome (SARS): Updated Recommendations, October 2004WHO PressGeneva, Switzerland2004 76.ZuZ.Y.JiangM.D.XuP.P.ChenW.NiQ.Q.LuG.M.ZhangL.J.Coronavirus" exact="disease" post="2019 (COVID-19): A perspective from ChinaRadiology202029610.1148/radiol.2020200490 77.AzharE.I.El-KafrawyS.A.FarrajS.A.HassanA.M.Al-SaeedM.S.HashemA.M.MadaniT.A.Evidence for camel-to-human"/>
  <result pre="of MERS coronavirusN. Engl. J. Med.20143702499250510.1056/NEJMoa140150524896817 78.collab: World Health OrganizationCoronavirus" exact="Disease" post="2019: Situation Report, 512020Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10(accessed on 11 March"/>
  <result pre="Dis.202010.1016/S1473-3099(20)30517-X 80.ZhaoJ.YuanQ.WangH.LiuW.LiaoX.SuY.WangX.YuanJ.LiT.LiJ.Antibody responses to SARS-CoV-2 in patients of novel coronavirus" exact="disease" post="2019Clin. Infect. Dis.202010.1093/cid/ciaa34432221519 81.DengS.-Q.PengH.-J.Characteristics of and public health responses"/>
  <result pre="Dis.202010.1093/cid/ciaa34432221519 81.DengS.-Q.PengH.-J.Characteristics of and public health responses to the coronavirus" exact="disease" post="2019 outbreak in ChinaJ. Clin. Med.2020957510.3390/jcm902057532093211 82.YangW.YanF.Patients with RT-PCR"/>
  <result pre="ChinaJ. Clin. Med.2020957510.3390/jcm902057532093211 82.YangW.YanF.Patients with RT-PCR confirmed COVID-19 and normal" exact="chest" post="CTRadiology202029510.1148/radiol.202020070232142398 83.ChanJ.F.-W.YipC.C.-Y.ToK.K.-W.TangT.H.-C.WongS.C.-Y.LeungK.-H.FungA.Y.-F.NgA.C.-K.ZouZ.TsoiH.-W.et al.Improved molecular diagnosis of COVID-19 by the"/>
  <result pre="al.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: A single-centered, retrospective, observational studyLancet Respir."/>
  <result pre="COVID-19 and treatmentJ. Infect.202010.1016/j.jinf.2020.03.037 96.SerbinaN.V.PamerE.G.Monocyte emigration from bone marrow during" exact="bacterial infection" post="requires signals mediated by chemokine receptor CCR2Nat. Immunol.2006731131710.1038/ni130916462739 97.StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.SmithD.RichardsonP.COVID-19:"/>
  <result pre="and treatmentJ. Infect.202010.1016/j.jinf.2020.03.037 96.SerbinaN.V.PamerE.G.Monocyte emigration from bone marrow during bacterial" exact="infection" post="requires signals mediated by chemokine receptor CCR2Nat. Immunol.2006731131710.1038/ni130916462739 97.StebbingJ.PhelanA.GriffinI.TuckerC.OechsleO.SmithD.RichardsonP.COVID-19:"/>
  <result pre="an evidence-based cureEBioMedicine20205210.1016/j.ebiom.2019.102614 105.GreinJ.OhmagariN.ShinD.DiazG.AspergesE.CastagnaA.FeldtT.GreenG.GreenM.L.LescureF.-X.Compassionate Use of Remdesivir for Patients with" exact="Severe" post="Covid-19N. Engl. J. Med.20203822327233610.1056/NEJMoa200701632275812 106.collab: Food and Drug Administration"/>
  <result pre="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment(accessed on 1 May 2020) 107.DongL.HuS.GaoJ.Discovering drugs to treat coronavirus" exact="disease" post="2019 (COVID-19)Drug Discov. Ther.202014586010.5582/ddt.2020.0101232147628 108.CaoB.WangY.WenD.LiuW.WangJ.FanG.RuanL.SongB.CaiY.WeiM.A trial of lopinavirâ€&quot;ritonavir in"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020210.1093/cid/ciaa23732150618 118.CavalcantiA.B.ZampieriF.G.RosaR.G.AzevedoL.C.VeigaV.C.AvezumA.DamianiL.P.MarcadentiA.Kawano-DouradoL.LisboaT.et al.Hydroxychloroquine"/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020210.1093/cid/ciaa23732150618 118.CavalcantiA.B.ZampieriF.G.RosaR.G.AzevedoL.C.VeigaV.C.AvezumA.DamianiL.P.MarcadentiA.Kawano-DouradoL.LisboaT.et al.Hydroxychloroquine with"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2)Clin. Infect. Dis.2020210.1093/cid/ciaa23732150618 118.CavalcantiA.B.ZampieriF.G.RosaR.G.AzevedoL.C.VeigaV.C.AvezumA.DamianiL.P.MarcadentiA.Kawano-DouradoL.LisboaT.et al.Hydroxychloroquine with or"/>
  <result pre="critically ill ICU patients with COVID-19Thromb. Res.202019114514710.1016/j.thromres.2020.04.01332291094 120.CattaneoM.BertinatoE.M.BirocchiS.BrizioC.MalavoltaD.ManzoniM.MuscarellaG.OrlandiM.Pulmonary embolism or" exact="pulmonary thrombosis" post="in COVID-19? Is the recommendation to use high-dose heparin"/>
  <result pre="ill ICU patients with COVID-19Thromb. Res.202019114514710.1016/j.thromres.2020.04.01332291094 120.CattaneoM.BertinatoE.M.BirocchiS.BrizioC.MalavoltaD.ManzoniM.MuscarellaG.OrlandiM.Pulmonary embolism or pulmonary" exact="thrombosis" post="in COVID-19? Is the recommendation to use high-dose heparin"/>
  <result pre="justified?Thromb. Haemost.202010.1055/s-0040-1712097 121.BarrettC.D.MooreH.B.YaffeM.B.MooreE.E.ISTH interim guidance on recognition and management of" exact="coagulopathy" post="in COVID-19: A CommentJ. Thromb. Haemost.2020182060206310.1111/jth.1486032302462 122.ShettyR.GhoshA.HonavarS.G.KhamarP.SethuS.Therapeutic opportunities to"/>
  <result pre="hypercoagulability of COVID-19J. Thromb. Haemost.202010.1111/jth.14849 131.GuptaR.GhoshA.SinghA.K.MisraA.Clinical considerations for patients with" exact="diabetes" post="in times of COVID-19 epidemicDiabetes Metab. Syndr.20201421210.1016/j.dsx.2020.03.002 132.GrantW.B.LahoreH.McDonnellS.L.BaggerlyC.A.FrenchC.B.AlianoJ.L.BhattoaH.P.Evidence that"/>
  <result pre="vitamin D supplementation could reduce risk of influenza and COVID-19" exact="infections" post="and deathsNutrients20201298810.3390/nu1204098832252338 133.LeT.T.AndreadakisZ.KumarA.RomÃ¡nR.G.TollefsenS.SavilleM.MayhewS.The COVID-19 vaccine development landscapeNat. Rev. Drug"/>
  <result pre="World Health OrganizationRational Use of Personal Protective Equipment for Coronavirus" exact="Disease" post="(COVID-19): Interim Guidance, 27 February 2020WHO PressGeneva, Switzerland2020 136.AdamsJ.G.WallsR.M.Supporting"/>
  <result pre="outbreak of COVID-19Eur. J. Nucl. Med. Mol. Imaging2020471632163310.1007/s00259-020-04779-x32215677 138.HamidS.MirM.Y.RohelaG.K.Noval coronavirus" exact="disease" post="(COVID-19): A pandemic (Epidemiology, Pathogenesis and potential therapeutics)New Microbes"/>
  <result pre="out of the cell to infect other cells. Figure 2" exact="Inflammatory" post="responses during severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection."/>
  <result pre="to infect other cells. Figure 2 Inflammatory responses during severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV-2) infection. SARS-CoV-2 attaches to the"/>
  <result pre="infect other cells. Figure 2 Inflammatory responses during severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV-2) infection. SARS-CoV-2 attaches to the ACE2"/>
  <result pre="other cells. Figure 2 Inflammatory responses during severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV-2) infection. SARS-CoV-2 attaches to the ACE2 receptor,"/>
  <result pre="ACE2 receptor, and the spike protein is cleaved by the" exact="type II" post="transmembrane serine protease (TMPRSS2), resulting in viral replication. Mature"/>
  <result pre="by the type II transmembrane serine protease (TMPRSS2), resulting in" exact="viral" post="replication. Mature viruses are released from the cell by"/>
  <result pre="These impaired-associated molecular forms can be detected by the neighboring" exact="epithelial" post="cells and other alveolar macrophages. In response, the pro-inflammatory"/>
  <result pre="and may damages the other organs as well. Figure 3" exact="Atypical" post="CT imaging of a 56-year-old female presented with a"/>
  <result pre="as well. Figure 3 Atypical CT imaging of a 56-year-old" exact="female" post="presented with a history of 3 days of persistent"/>
  <result pre="history of 3 days of persistent fever. Laboratory findings: reduced" exact="total" post="protein level (54.0 g/L), reduced albumin value (35.5 g/L),"/>
  <result pre="right lung lobe covered GGO. (B) Patchy GGO in the" exact="upper" post="part of the right lung with sporadic consolidated lesions."/>
  <result pre="license [69]. ijerph-17-05904-t001_Table 1Table 1 Case fatality ratio of Coronavirus" exact="Disease" post="2019 (COVID-19) in major countries of the world *."/>
  <result pre="countries of the world *. CFR, case fatality ratio. Territory" exact="Total" post="Confirmed Cases Total Deaths CFR France 167,456 30,060 17.95"/>
  <result pre="world *. CFR, case fatality ratio. Territory Total Confirmed Cases" exact="Total" post="Deaths CFR France 167,456 30,060 17.95 Belgium 296,381 45,501"/>
  <result pre="Australia 12,896 128 0.99 Saudi Arabia 258,156 2601 1.00 Grand" exact="total" post="8,482,781 434,541 5.12 * World Health Organization (2020). COVID-19"/>
  <result pre="with the severity of COVID-19 [48,66]. Clinical Type Symptoms Mild" exact="disease" post="No signs of pneumonia; it happened in 81% of"/>
  <result pre="No signs of pneumonia; it happened in 81% of patients." exact="Severe" post="disease Oxygen saturation of blood â‰¤93%, infiltration of lungs"/>
  <result pre="signs of pneumonia; it happened in 81% of patients. Severe" exact="disease" post="Oxygen saturation of blood â‰¤93%, infiltration of lungs â‰¥50%"/>
  <result pre="within one or two days. The ratio of PaO2/FiO2 (oxygen" exact="partial" post="pressure/fraction of inspired oxygen) &amp;lt;300. GGO (ground glass opacities):"/>
  <result pre="inspired oxygen) &amp;lt;300. GGO (ground glass opacities): 14% of cases" exact="acquired" post="severe symptoms. Critical disease Failure of the respiratory system,"/>
  <result pre="(ground glass opacities): 14% of cases acquired severe symptoms. Critical" exact="disease" post="Failure of the respiratory system, septic shock, concerted organ"/>
  <result pre="glass opacities): 14% of cases acquired severe symptoms. Critical disease" exact="Failure" post="of the respiratory system, septic shock, concerted organ dysfunction,"/>
  <result pre="of cases acquired severe symptoms. Critical disease Failure of the" exact="respiratory" post="system, septic shock, concerted organ dysfunction, or multiple organ"/>
  <result pre="acquired severe symptoms. Critical disease Failure of the respiratory system," exact="septic shock," post="concerted organ dysfunction, or multiple organ failure (MOF); it"/>
  <result pre="NCT04320277 Cenicriviroc (not approved) CCR2 and CCR5 antagonist CCR2 Promotes" exact="monocyte" post="recruitment in tissues Clinical trial in progress Sargramostim GM-CSF"/>
  <result pre="interferons. Drug Type Mechanism Recommendation Remdesivir Antiviral Remdesivir targets the" exact="viral" post="RNA polymerases to inhibit the replication of the virus,"/>
  <result pre="Clinical trials have been conducted Favipiravir Antiviral Favipiravir interacts with" exact="viral" post="RNA polymerase, thus inhibiting viral replication Efficacy has been"/>
  <result pre="Favipiravir Antiviral Favipiravir interacts with viral RNA polymerase, thus inhibiting" exact="viral" post="replication Efficacy has been proven Convalescent plasma Antiviral Convalescent"/>
  <result pre="Efficacy has been proven IFNs Immuno-enhancer IFNs interfere with the" exact="viral" post="RNA transcription and translation of protein, and thus inhibit"/>
  <result pre="viral RNA transcription and translation of protein, and thus inhibit" exact="viral" post="replication Clinical trials have been conducted, and efficacy has"/>
  <result pre="as limits the damaging effects of cytokines Clinical trials underway" exact="Vitamin C" post="Nutritional supportive management Vitamin C strengthens the immunity response"/>
  <result pre="of cytokines Clinical trials underway Vitamin C Nutritional supportive management" exact="Vitamin C" post="strengthens the immunity response by increasing IFN production and"/>
  <result pre="Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine (BCG-CORONA)" exact="Multiple" post="sites in the Netherlands NCT04328441 SARS-CoV-2 inactivated vaccine Randomized"/>
  <result pre="SARS-CoV-2 Inactivated Vaccine in Healthy Adults Suining County Center for" exact="Disease" post="Control and Prevention in China NCT04352608 mRNA-1273 Non-Randomized Safety"/>
  <result pre="Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2" exact="Infection" post="(COVID-19) Multiple sites in America NCT04283461 LV-SMENP-DC vaccine and"/>
  <result pre="of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)" exact="Multiple" post="sites in America NCT04283461 LV-SMENP-DC vaccine and antigen-specific CTLs"/>
  <result pre="Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus" exact="Disease" post="(COVID-19) Vaccine ChAdOx1 nCoV-19 vaccine Multiple sites in United"/>
  <result pre="of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 vaccine" exact="Multiple" post="sites in United Kingdom NCT04400838 Inactivated SARS-CoV-2 Vaccine Randomized"/>
  <result pre="SARS-CoV-2 vaccine in Healthy People Aged 18 to 59 Years" exact="Multiple" post="sites in China NCT04412538 BCG, Bacillus Calmetteâ€&quot;GuÃ©rin; a clinical"/>
 </snippets>
</snippetsTree>
